The Food and Drug Administration (FDA) has approved the first stent to treat coronary artery disease that is absorbed by the body over time, offering an alternative to metallic stents that remain in the body permanently. The device, called the Absorb GT1 Bioresorbable Vascular Scaffold System (BVS), is manufactured by Abbott Laboratories. It is implanted in the artery after an angioplasty, or surgery to repair a blocked blood vessel, and is gradually absorbed by the body in about three years. The stent releases a drug called everolimus that limits the growth of scar tissue, which can narrow arteries, a condition ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.